Literature DB >> 9453054

The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues.

Y Nabuchi1, E Fujiwara, H Kuboniwa, Y Asoh, H Ushio.   

Abstract

PURPOSE: The stability of recombinant human parathyroid hormone (rhPTH) was examined under acidic to alkaline conditions; its degradation pathways were elucidated from resultant products.
METHODS: Degradation assay was performed in the pH range 2 to 10 at 40, 50 and 60 degrees C. The approximate molecular mass and pI values of the degradation products were estimated by electrophoresis. FAB-MS peptide mapping and amino acid composition analysis were used to determine these structures. The amount of each respective product was determined by HPLC.
RESULTS: At pH2, eight degradation products were found: 1-30rhPTH, 1-74rhPTH, 1-71rhPTH, 1-56rhPTH, 1-45rhPTH, 46-84rhPTH, 31-84rhPTH and Asp76-rhPTH; these were mainly as a consequence of peptide bond cleavage of the amide bond of Asp. At pH9, five products were found: isoAsp16-rhPTH, Asp16-rhPTH, Asp57-rhPTH, Asp76-rhPTH, 17-84rhPTH; the main degradation pathway was deamidation of Asn via a cyclic imide intermediate. Degradation products resulting from cleavage at Asp were increased in proportion to the extent that pH was lowered below 5. As pH was increased above 5, so were products resulting from deamidation of Asn. Correspondingly, levels of intact rhPTH were at a peak at pH5.
CONCLUSIONS: Degradation of rhPTH under acidic conditions predominantly occurs by cleavage at Asp, whereas, above pH5, deamidation of Asn is the more prominent, rhPTH is most stable at pH5.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9453054     DOI: 10.1023/a:1012115426306

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides.

Authors:  K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

2.  Cleavage at aspartyl-prolyl bonds.

Authors: 
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

3.  Structure of recombinant human parathyroid hormone in solution using multidimensional NMR spectroscopy.

Authors:  W Gronwald; D Schomburg; M P Harder; H Mayer; J Paulsen; E Wingender; V Wray
Journal:  Biol Chem Hoppe Seyler       Date:  1996-03

4.  Beta-aspartyl peptides in enzymatic hydrolysates of protein.

Authors:  E E Haley; B J Corcoran; F E Dorer; D L Buchanan
Journal:  Biochemistry       Date:  1966-10       Impact factor: 3.162

5.  Peptide mapping of recombinant human parathyroid hormone by enzymatic digestion and subsequent fast-atom bombardment mass spectrometry.

Authors:  Y Nabuchi; H Kuboniwa; H Takasu; Y Asoh; H Ushio
Journal:  Rapid Commun Mass Spectrom       Date:  1995       Impact factor: 2.419

6.  Oxidation of recombinant human parathyroid hormone: effect of oxidized position on the biological activity.

Authors:  Y Nabuchi; E Fujiwara; K Ueno; H Kuboniwa; Y Asoh; H Ushio
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

7.  Expression of human parathyroid hormone-(1-84) in Escherichia coli as a factor X-cleavable fusion protein.

Authors:  T J Gardella; D Rubin; A B Abou-Samra; H T Keutmann; J T Potts; H M Kronenberg; S R Nussbaum
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

8.  Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide.

Authors:  C Oliyai; R T Borchardt
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

9.  Major degradation products of basic fibroblast growth factor: detection of succinimide and iso-aspartate in place of aspartate.

Authors:  Z Shahrokh; G Eberlein; D Buckley; M V Paranandi; D W Aswad; P Stratton; R Mischak; Y J Wang
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

10.  The structure of human parathyroid hormone from a study of fragments in solution using 1H NMR spectroscopy and its biological implications.

Authors:  V Wray; T Federau; W Gronwald; H Mayer; D Schomburg; W Tegge; E Wingender
Journal:  Biochemistry       Date:  1994-02-22       Impact factor: 3.162

View more
  6 in total

1.  Parathyroid hormone PTH(1-34) formulation that enables uniform coating on a novel transdermal microprojection delivery system.

Authors:  Mahmoud Ameri; Shelley C Fan; Yuh-Fun Maa
Journal:  Pharm Res       Date:  2009-12-15       Impact factor: 4.200

2.  The RAPID method for blood processing yields new insight in plasma concentrations and molecular forms of circulating gut peptides.

Authors:  Andreas Stengel; David Keire; Miriam Goebel; Lena Evilevitch; Brian Wiggins; Yvette Taché; Joseph R Reeve
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

3.  A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood.

Authors:  Pauline Teuffel; Miriam Goebel-Stengel; Tobias Hofmann; Philip Prinz; Sophie Scharner; Jan L Körner; Carsten Grötzinger; Matthias Rose; Burghard F Klapp; Andreas Stengel
Journal:  J Vis Exp       Date:  2016-04-28       Impact factor: 1.355

4.  Demonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system.

Authors:  Mahmoud Ameri; Peter E Daddona; Yuh-Fun Maa
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

5.  Mammalian Hsp22 is a heat-inducible small heat-shock protein with chaperone-like activity.

Authors:  Tirumala Kumar Chowdary; Bakthisaran Raman; Tangirala Ramakrishna; Chintalagiri Mohan Rao
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

6.  Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product.

Authors:  Piroska Kovács; Tamás Schäfer; Viktor Háda; Helga Hevér; Sonja Klingelhöfer; Merle Nebel; Tanja Stadie; Róbert Kiss; Zoltán Urbányi
Journal:  BioDrugs       Date:  2020-02       Impact factor: 5.807

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.